08:56 AM EDT, 04/27/2026 (MT Newswires) -- Intellia Therapeutics (NTLA) said Monday its phase 3 clinical trial for a single-dose gene-editing therapy for hereditary angioedema met its primary and all key secondary endpoints.

The experimental medication reduced swelling episodes by 87% versus placebo during a six-month evaluation period, the company said.

The company reported favorable safety and tolerability data, with no serious adverse events observed in the treatment arm.

Management initiated a rolling biologics license application with the US Food and Drug Administration and anticipates a US launch in the first half of 2027, if approved, it said.

Shares of the company were up 4.7% in Monday premarket activity.